Edition:
United States

Oncopeptides AB (ONCO.ST)

ONCO.ST on Stockholm Stock Exchange

82.50SEK
11 Dec 2017
Change (% chg)

2.50kr (+3.12%)
Prev Close
80.00kr
Open
80.00kr
Day's High
83.75kr
Day's Low
79.50kr
Volume
66,386
Avg. Vol
39,149
52-wk High
84.50kr
52-wk Low
41.10kr

Latest Key Developments (Source: Significant Developments)

Oncopeptides Q3 operating ‍loss widens to SEK 51.6 million
Wednesday, 15 Nov 2017 02:04am EST 

Nov 15 (Reuters) - ONCOPEPTIDES AB :Q3 OPERATING ‍LOSS SEK 51.6 MILLION VERSUS LOSS SEK 24.7 MILLION YEAR AGO​.  Full Article

Oncopeptides Q2 loss for period widens to SEK 67.3 mln​
Friday, 25 Aug 2017 02:00am EDT 

Aug 25 (Reuters) - ONCOPEPTIDES AB :‍Q2 LOSS FOR PERIOD WAS 67.3 (LOSS: 23.5) MSEK​.  Full Article

Oncopeptides Q1 net loss SEK 62.1 million
Thursday, 18 May 2017 02:00am EDT 

May 18 (Reuters) - ONCOPEPTIDES AB :Q1 NET SALES AMOUNTED TO 0.0 (0.0) MSEK.Q1 LOSS FOR PERIOD WAS 62.1 (LOSS: 15.2) MSEK.  Full Article

Oncopeptides receives additional patent protection for Ygalo in Europe
Tuesday, 21 Mar 2017 03:45am EDT 

Oncopeptides AB : European patent office recently issued a notice that they intend to grant an additional European patent to Oncoeptides . Additional patent protection for Ygalo is valid April 2032 .Patent (EP2701720) covers inter alia lyophilized formulation of Ygalo that is intended to be launched.  Full Article

BRIEF-Oncopeptides Q3 operating ‍loss widens to SEK 51.6 million

* Q3 OPERATING ‍LOSS SEK 51.6 MILLION VERSUS LOSS SEK 24.7 MILLION YEAR AGO​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)